Miami-based RapidPulse has raised $48 million in a Series B financing round as the medical technology startup advances a stroke treatment platform that has attracted backing from both venture investors and strategic healthcare players.
The financing was co-led by Medtronic, TechWald Next S.p.A. and S3 Ventures. New investors SBI Investment Company Ltd. and Florida Opportunity Fund also participated alongside existing backers Santé Ventures, Syntheon, Hatteras Venture Partners and Epidarex Capital.
RapidPulse said it will use the funding to complete its ongoing Investigational Device Exemption (IDE) clinical study, known as TURBO, while continuing to expand its proprietary aspiration technology platform. The company is also preparing, pending clinical data, to pursue U.S. Food and Drug Administration approval for its stroke treatment system.
“This financing enables us to complete the TURBO study, expand clinical experience across leading stroke centers, and data permitting, seek FDA approval for the RapidPulse system,” said RapidPulse CEO Sean McBrayer, in a statement. “We are particularly encouraged by the support of both leading financial investors and one of the largest medical technology companies in the world, Medtronic, reflecting growing recognition of the potential impact of our approach to stroke treatment.”
The raise underscoring continued investor appetite for companies with proprietary technology and defined paths toward commercialization. It also comes at a time when investors remain selective about backing medical device companies, often favoring businesses with clear clinical and regulatory milestones.
RapidPulse is developing a mechanical thrombectomy system designed to treat acute ischemic stroke, the most common type of stroke, by removing blood clots from blocked arteries in the brain. The company’s technology uses a pulsed aspiration approach that is intended to improve clot engagement and removal compared with conventional aspiration methods.
TechWald Next CEO Alessandro Piga said the firm evaluated numerous stroke technologies before selecting RapidPulse. “The company combines differentiated technology, strong intellectual property, and an experienced leadership team. We are excited to support RapidPulse as it advances through this next stage of clinical development.”
RapidPulse was spun out of Syntheon and is headquartered in Miami. The company is conducting clinical studies in both the United States and Europe as it works toward commercialization.
The financing reflects continued investor interest in companies developing technologies for stroke care, one of the largest markets in neurovascular medicine. While the company remains in the clinical stage, the new funding provides runway to generate pivotal data and reach key regulatory milestones that could position RapidPulse for eventual commercialization or future strategic partnerships.
For Miami’s startup ecosystem, the round adds another notable venture financing to support the region’s growth in healthcare innovation, South Florida’s second most active sector for venture capital activity behind financial technology.
READ MORE IN REFRESH MIAMI:
- Pediatrica secures $28M Series B to expand platform across Florida, Texas
- Delorean AI wants to give doctors something they’ve never had: A glimpse into the future
- With Minu acquisition, Miami-based unicorn Betterfly doubles down on U.S. growth
- DermaSensor is expanding internationally with its skin-cancer detection device, receives $5M investment
- Sofya wants to turn physician vibe coding into real healthcare AI
- Miami-based RapidPulse secures $48M Series B co-led by Medtronic to transform stroke treatment – July 16, 2026
- 8+ things to know in #MiamiTech: News about Ken Griffin, Zulu Pods, Tamiami Angel Funds, Uber Eats, FC 100, XSponse, ExchangiFi, GoTu, Brightline, job opps & more – July 10, 2026
- Miami area startups attracted $832M in VC in Q2, PitchBook reports. We’ve got the top deals. – July 9, 2026
